Preliminary study of chemosenstivity tests in osteosarcoma using a histoculture drug response assay.
BACKGROUND
The clinical efficacy of chemotherapy is strongly correlated with the histoculture drug response assay (HDRA) in various types of cancers. However, there have been no previous reports on its use in osteosarcoma.


METHODS
Thirty-six fresh samples of human osteosarcoma were evaluated by the HDRA method in order to determine its possible usefulness in the treatment of this cancer. All the materials were obtained either during biopsy or surgical excision at our hospital, between January 2003 and October 2005.


RESULTS
A significant inhibition rate in primary biopsies was observed with Adriamycin (ADM) (47.3+/-15.3%); Cisplatin (CDDP) (36.3+/-22.3%); and Carboplatin (CBP) (50.5+/-23.3%); treatment. ADM and CBP demonstrated a statistically significant increase in inhibition rates compared to the other drugs.


CONCLUSIONS
Even though the HDRA method has many limitations, it might be a feasible and useful technique for selecting and predicting the efficacy of anticancer drugs for osteosarcoma patients.
Lee
Soo Yong
SY
Department of Orthopaedic Surgery, Korea Cancer Center Hospital, Seoul, Korea.
Jeon
Dae Geun
DG
Cho
Wan Hyung
WH
Song
Won Seok
WS
Kim
Moon Bo
MB
Park
Jong Hoon
JH
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001706:Biopsy; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002648:Child; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012516:Osteosarcoma / Q000188:drug therapy* / Q000473:pathology
D000970:Antineoplastic Agents